Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Intellia Therapeutics Inc

NTLA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: HOLD

Last Close

$11.91

▲ +0.68%

Market Cap $1.67B · Vol 697.53K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.67B

Small Cap

Div Yield

N/A

EPS Growth

+16.33%

YoY

RSI (14)

67.92

Momentum

Beta

1.81

vs Market

52W High

$28.24

57.83% below

52W Low

$7.95

49.81% above

Volume

697.53K

Avg 1.22M

P/B

1.56

Price-to-book

ROE

-53.48%

Return on equity

Free Float

96.08%

Public shares

Shariah Compliance8 STANDARDS

✗ Intellia Therapeutics Inc (NTLA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NTLA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.25%

-10.45%

-9.01%

+0.34%

YTD

+32.48%

+9.27%

-69.31%

-92.34%

Financials & Valuation

TTM · Annual

Total Revenue	$67.67M
Net Income	$-412,694,000.00
Revenue Growth (YoY)	-46.23%
Gross Margin	100.00%
Operating Margin	-651.67%
Net Profit Margin	-609.85%
ROE	-53.48%
ROA · ROIC	-40.60% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	14.40
P/B	1.56
P/FCF	N/A
EPS Growth	+16.33%
Outstanding Shares	140.13M

Technical Indicators

50-Day SMA	$13.38
200-Day SMA	$12.43
RSI (14)	67.92
Beta	1.81
52-Week High	$28.24
52-Week Low	$7.95

Volume Today	697.53K
Avg Daily Volume (30D)	1.22M
Relative Volume	0.57x
Volatility (10D)	42.39
Volatility (30D)	63.09
Free Float	96.08%

Analyst Consensus

HOLD

Current Price $11.91

Mean Target $24.80

52W Low$7.95 52W High$28.24

Current

Target

$7.95 $28.24

Current Analyst target

+108.23% upside potential · 17 analysts

Identifiers

ExchangeNasdaq

FIGIBBG007KC7PC9

ISINUS45826J1051

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.